Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CTRC | Q99895 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135865 | 0.92 | CTSS (0.41) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL5863065 | 0.87 | CTSK (0.45) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL1854385 | 0.78 | KDM4E (0.37) | CTSL | |
| SCHEMBL13505874 | 0.74 | CTSK (0.44) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL27200289 | 0.74 | HDAC4 (0.60) | CTSSCTSKSIRT5CTSLCTSB | |
| SCHEMBL27200285 | 0.74 | HDAC4 (0.60) | CTSSCTSKSIRT5CTSLCTSB | |
| SCHEMBL15771853 | 0.73 | PPARA (0.49) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL15771851 | 0.73 | PPARA (0.49) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL3314258 | 0.73 | NPFFR1 (0.39) | — | |
| SCHEMBL15772496 | 0.73 | CTSS (0.44) | CTSSCTSKCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198438-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2134716-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008131050-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113454-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, LCK, MAP3K15 | CTSS 1682/4885CTSK 652/4885SIRT5 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.